Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022

During the 2021-2022 US influenza season, circulating A(H3N2) viruses were antigenically different than the vaccine. Vaccine effectiveness against hospitalized illness was 26% (95% CI: -14-52%) for adults 18-64-years and -3% (95% CI: -54-31) for adults >= 65-years. Background The COVID-19 pandemic was associated with historically low influenza circulation during the 2020-2021 season, followed by an increase in influenza circulation during the 2021-2022 US season. The 2a.2 subgroup of the influenza A(H3N2) 3C.2a1b subclade that predominated was antigenically different from the vaccine strain. Methods To understand the effectiveness of the 2021-2022 vaccine against hospitalized influenza illness, a multistate sentinel surveillance network enrolled adults aged >= 18 years hospitalized with acute respiratory illness and tested for influenza by a molecular assay. Using the test-negative design, vaccine effectiveness (VE) was measured by comparing the odds of current-season influenza vaccination in influenza-positive case-patients and influenza-negative, SARS-CoV-2-negative controls, adjusting for confounders. A separate analysis was performed to illustrate bias introduced by including SARS-CoV-2-positive controls. Results A total of 2334 patients, including 295 influenza cases (47% vaccinated), 1175 influenza- and SARS-CoV-2-negative controls (53% vaccinated), and 864 influenza-negative and SARS-CoV-2-positive controls (49% vaccinated), were analyzed. Influenza VE was 26% (95% CI: -14% to 52%) among adults aged 18-64 years, -3% (-54% to 31%) among adults aged >= 65 years, and 50% (15-71%) among adults aged 18-64 years without immunocompromising conditions. Estimated VE decreased with inclusion of SARS-CoV-2-positive controls. Conclusions During a season where influenza A(H3N2) was antigenically different from the vaccine virus, vaccination was associated with a reduced risk of influenza hospitalization in younger immunocompetent adults. However, vaccination did not provide protection in adults >= 65 years of age. Improvements in vaccines, antivirals, and prevention strategies are warranted.

Automated summary

During the 2021-2022 US influenza season, circulating A(H3N2) viruses were antigenically different from the vaccine. The vaccine effectiveness against hospitalized illness was 26% (95% CI: -14-52%) for adults 18-64 years old and -3% (95% CI: -54-31%) for adults ≥ 65 years old. Our study showed that the influenza vaccine had some effectiveness in preventing hospitalization among immunocompetent adults aged 18-64, but provided no significant protection for adults ≥ 65.